Pfizer has penned a deal with South San Francisco’s Ab Initio that will help fund the fledgling company’s platform expansion. The company has been partnering with Pfizer to “discover novel therapeutic antibodies against an undisclosed target in the G-protein coupled receptor (GPCR) superfamily.” … ​more

Merck KGaA, Darmstadt, Germany and Pfizer have announced the opening of trial sites for an international Phase III study of avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in patients with platinum-resistant/refractory ovarian cancer​ … more

The FDA has accepted for review a supplemental New Drug Application for Pfizer’s breast cancer medication, IBRANCE® (palbociclib). If approved, the application would expand the approved use of IBRANCE to reflect findings from the Phase 3 PALOMA-3 trial, which evaluated IBRANCE in combination with fulvestrant versus fulvestrant plus placebo in women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+, HER2-) metastatic breast cancer​ … ​more